Abstract
Background/Aim: Many patients with brain metastases from melanoma receive whole-brain radiotherapy (WBRT). WBRT-regimens must consider the patient's prognosis in order to deliver the best therapy. Patients and Methods: Seven factors were correlated to intracerebral control and survival after WBRT alone in 92 patients with melanoma: WBRT regimen, age at WBRT, gender, Karnofsky performance score (KPS), number of brain lesions, number of extracranial metastatic sites, and time from melanoma diagnosis to WBRT. Results: On univariate analyses, KPS ≥80 (p=0.075) showed a trend towards improved intracerebral control. Greater WBRT dose (p=0.029), age ≤60 years (p=0.002), KPS ≥80 (p<0.001) and no extracranial site (p=0.008) were positively correlated with survival. On multivariate analyses, KPS (hazard ratio=2.11, 95% confidence interval=1.28-3.47; p=0.003) and number of extracranial metastatic sites (hazard ratio=1.27, 95% confidence interval=1.02-1.56; p=0.030) maintained significance regarding survival. Conclusion: The study identified predictors of survival for patients with melanoma receiving WBRT for brain metastases that can contribute to selection of individualized therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 6637-6640 |
| Number of pages | 4 |
| Journal | Anticancer Research |
| Volume | 36 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2016 |
Fingerprint
Keywords
- Brain metastases
- Malignant melanoma
- Prognoses
- Treatment results
- Whole-brain radiotherapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Prognostic factors after whole-brain radiotherapy alone for brain metastases from malignant melanoma. / Rades, Dirk; Sehmisch, Lena; Janssen, Stefan; Schild, Steven E.
In: Anticancer Research, Vol. 36, No. 12, 01.12.2016, p. 6637-6640.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic factors after whole-brain radiotherapy alone for brain metastases from malignant melanoma
AU - Rades, Dirk
AU - Sehmisch, Lena
AU - Janssen, Stefan
AU - Schild, Steven E.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background/Aim: Many patients with brain metastases from melanoma receive whole-brain radiotherapy (WBRT). WBRT-regimens must consider the patient's prognosis in order to deliver the best therapy. Patients and Methods: Seven factors were correlated to intracerebral control and survival after WBRT alone in 92 patients with melanoma: WBRT regimen, age at WBRT, gender, Karnofsky performance score (KPS), number of brain lesions, number of extracranial metastatic sites, and time from melanoma diagnosis to WBRT. Results: On univariate analyses, KPS ≥80 (p=0.075) showed a trend towards improved intracerebral control. Greater WBRT dose (p=0.029), age ≤60 years (p=0.002), KPS ≥80 (p<0.001) and no extracranial site (p=0.008) were positively correlated with survival. On multivariate analyses, KPS (hazard ratio=2.11, 95% confidence interval=1.28-3.47; p=0.003) and number of extracranial metastatic sites (hazard ratio=1.27, 95% confidence interval=1.02-1.56; p=0.030) maintained significance regarding survival. Conclusion: The study identified predictors of survival for patients with melanoma receiving WBRT for brain metastases that can contribute to selection of individualized therapies.
AB - Background/Aim: Many patients with brain metastases from melanoma receive whole-brain radiotherapy (WBRT). WBRT-regimens must consider the patient's prognosis in order to deliver the best therapy. Patients and Methods: Seven factors were correlated to intracerebral control and survival after WBRT alone in 92 patients with melanoma: WBRT regimen, age at WBRT, gender, Karnofsky performance score (KPS), number of brain lesions, number of extracranial metastatic sites, and time from melanoma diagnosis to WBRT. Results: On univariate analyses, KPS ≥80 (p=0.075) showed a trend towards improved intracerebral control. Greater WBRT dose (p=0.029), age ≤60 years (p=0.002), KPS ≥80 (p<0.001) and no extracranial site (p=0.008) were positively correlated with survival. On multivariate analyses, KPS (hazard ratio=2.11, 95% confidence interval=1.28-3.47; p=0.003) and number of extracranial metastatic sites (hazard ratio=1.27, 95% confidence interval=1.02-1.56; p=0.030) maintained significance regarding survival. Conclusion: The study identified predictors of survival for patients with melanoma receiving WBRT for brain metastases that can contribute to selection of individualized therapies.
KW - Brain metastases
KW - Malignant melanoma
KW - Prognoses
KW - Treatment results
KW - Whole-brain radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85002377961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002377961&partnerID=8YFLogxK
U2 - 10.21873/anticanres.11271
DO - 10.21873/anticanres.11271
M3 - Article
C2 - 27919995
AN - SCOPUS:85002377961
VL - 36
SP - 6637
EP - 6640
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 12
ER -